|Bid||13.400 x 1300|
|Ask||13.450 x 800|
|Day's Range||13.100 - 13.475|
|52 Week Range||6.600 - 19.900|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Iovance Biotherapeutics stock toppled by double digits Thursday after a third of patients who received its experimental lung cancer regimen worsened following treatment.
Investors need to pay close attention to Lion Biotechnologies (IOVA) stock based on the movements in the options market lately.
The San Carlos, California-based company said it had a loss of 34 cents per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
Iovance Biotherapeutics Inc’s (NASDAQ:IOVA): Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient’s immune system to eradicateRead More...
Investors need to pay close attention to Iovance Biotherapeutics (IOVA) stock based on the movements in the options market lately.
RXi reported revenues of $23,000 for the quarter from grants related to BioAxone’s work in spinal cord injury, compared to zero in revenues in 1Q:17. Following the availability of the trial results, RXi will set up data rooms for interested buyers.
The San Carlos, California-based company said it had a loss of 31 cents per share. Losses, adjusted for stock option expense, came to 26 cents per share. The results beat Wall Street expectations. The ...
Morphogenesis is part of the burgeoning life science sector that state and local economic development officials want to expand. It’s one of at least three companies establishing offices that are near Moffitt, a national leader in cancer treatment.
On a per-share basis, the San Carlos, California-based company said it had a loss of 36 cents. Losses, adjusted for stock option expense, came to 32 cents per share. The results met Wall Street expectations. ...
Lion Biotechnologies (IOVA) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
Iovance Biotherapeutics Inc (NASDAQ:IOVA), a $1.45B small-cap, operates in the healthcare industry, which faces demand for new drug development to meet new or persistent chronic illnesses, and ongoing need forRead More...